Health news
The Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of refractory, moderate to severe atopic dermatitis in patients 12 years of age and older whose disease is not adequately controlled with…
Atopic dermatitis is associated with shorter stature, increased body mass index (BMI), and lower weight in early childhood, although the associations with height and BMI are attenuated as the children age, according to study data…
Treatment with lebrikizumab plus topical corticosteroids (TCS) was associated with significant skin improvement in patients with moderate to severe atopic dermatitis, according to data from the phase 3 ADhere trial. Lebrikizumab is a novel humanized…
Hair loss is separated into two categories. Cicatricial alopecia, characterized by inflammation that permanently damages the hair follicle, is uncommon. In clinical practice, noncicatricial types make up the majority of cases of alopecia. Whereas male…
The Food and Drug Administration (FDA) has granted Fast Track designation to orismilast tablet for the treatment of moderate to severe atopic dermatitis. Orismilast is a selective next generation phosphodiesterase-4 (PDE4) inhibitor with broad anti-inflammatory…
Worsening of atopic dermatitis (AD) during pregnancy is uncommon but may be associated with premenstrual syndrome (PMS), study data published in the Journal of the American Academy of Dermatology suggests. Research suggests that changes in…
Oral and topical antifungals are effective for patients with atopic dermatitis (AD) who develop dupilumab facial redness (DFR) after receiving dupilumab treatment, researchers reported in a study published in Dermatologic Therapy. The investigators reviewed data…
Severe atopic dermatitis (AD) is associated with symptoms of depression and internalizing behaviors throughout childhood and adolescence, researchers reported in a study published in JAMA Dermatology. The longitudinal cohort study analyzed data from September 6,…
The Food and Drug Administration has approved Opzelura (ruxolitinib) cream for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 12 years of age and older whose disease is…
The safety profiles of several systemic immunomodulatory agents in adults with atopic dermatitis (AD) were outlined in study data published in the Journal of the American Academy of Dermatology. In a population-based cohort of patients…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021